Pilot Influenza Challenge Study

NCT ID: NCT07063849

Last Updated: 2025-07-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-20
• Study Completion Date: 2026-06-30

Brief Summary

This is a research study to understand what happens when a person is infected with influenza ("flu") and how the body controls the infection. Healthy participants (challenge) will be infected with a strain of flu (H3N2), and followed to see what symptoms occur and when they occur. Blood will be drawn and nasopharyngeal (NP) swabs will be collected before participants are infected to understand if having antibodies can protect participants from flu infection or lead to a milder flu illness. Blood will also be drawn and NP swabs collected after participants are infected to understand how and when the body's immune response to flu occurs. Participants will also breathe through a device for virus collection every other day.

Participants will be screened during one or more visits and will stay in the inpatient challenge unit for at least 10 days, maybe longer. Participants will complete a FLU PRO Diary Card daily. Blood will be drawn before the challenge and on Days 2, 4, and 8 while in the inpatient unit. NP samples will be taken every day to check for viruses and on certain days, immune responses such as antibodies. If on Day 8 (7 days after the challenge) the participant still has flu virus, medicine will be offered to treat the flu and the participant will be asked to stay in the challenge unit until NP swabs are negative for 2 consecutive days. Once the participant is discharged from the challenge unit, they will be asked to return to the clinic for 3 more visits. At the end of the study will be a final phone call.

Detailed Description

This experimental pilot study is designed to develop methods to analyze viral complexity shed after experimental human infection with influenza A virus, a necessary first step in the development of mucosal transmission models. While the initial influenza CHIM study at SLU employed an H1N1 influenza strain, in this study, an H3N2 strain will be used. Data reported from the first-in-human, dose-finding study for the DMID- and CIVICs-developed, RG-A/Texas/71/2017 (H3N2). Similarly, while the use of different clinical scoring rubrics prevents direct comparisons, illness observed during DMID 18-0010 was reported to be very mild, and lacked a sham inoculum comparator group, but the raw data are not available for review. In contrast, with RG-A/Texas/71/2017 (H3N2), participants reported a mean cumulative MJS of 25.8 (range 18.3 to 34.1) from day 2 through day 8; the MJS ranges from 0 to 36 for each measurement. In contrast, both of the sham inoculated participants had a cumulative MJS of 1.0. These observations are consistent with comparisons between H1N1 and H3N2 during naturally acquired infection. Thus, the H3N2 CHIM may be more amenable to studies of shed virus and mucosal immunity, and to provide a wider dynamic range of influenza illness against which to test vaccine and treatment countermeasures in the future. This study will examine the genetic diversity of shed influenza virus particles in small (<5µm) versus large (≥5µm) exhaled particles, as well as in nasopharyngeal swab samples, and compare the viral diversity in these specimens stratified by baseline serum microneutralization titer and nasopharyngeal mucosal IgA titers. While this is a small, exploratory study, not powered for statistical significance of endpoints, the aim is to develop the methods necessary for future, larger scale studies to apply this practical knowledge to further understand mucosal immune correlates of protection against influenza A disease. This understanding will be valuable for the development and testing of new influenza vaccines that better leverage mucosal immunity against influenza infection and transmission.

This is a CHI study of Influenza RG- A/Texas/71/2017 (H3N2) influenza, clade 3C3a virus to assess clinical response, immunological response, and safety. The study population will be healthy participants (male and non-pregnant, non-breastfeeding females) between the ages of 18 to 45, inclusive. Up to 12 participants will receive H3N2 virus CHI. Clinical manifestations, viral shedding, and immunological responses will be characterized.

Influenza RG-A/Texas/71/2017 (H3N2) influenza, clade 3C3a virus CHI will be performed using a 12 mL dose of approximately 1.86 x10^6 TCID50/mL, which has been shown to induce 60% or higher rates of MMID. The primary objective of the study will be to evaluate the association of MMID post-challenge and pre-existing virus-specific HAI titers in healthy participants. MMID is defined as the presence of both of the following, assessed through Day 8:

• Viral shedding detected by any approved positive RT-PCR assay from a NP swab, and
• Any one or more of the following symptoms or signs or laboratory findings, as related to the study agent; Arthralgia, Chest tightness, Chills, Conjunctivitis, Nasal congestion, Sinus Congestion, Coryza, Decreased appetite, Diarrhea, Dry Cough, Dyspnea/Shortness of Breath, Fatigue/Tiredness, Fever (>38.0°C), Headache, Lymphopenia (<1000 cells/mL), Myalgia, Nausea, Oxygen Saturation Decrease by ≥3% from baseline, Productive Cough, Rhinorrhea, Sore Throat, and Sweats.

During Study Days -30 to -3 (Screening Period), participants will provide informed consent to participate in this study. They will undergo a review of medical history, physical examination by a study physician, and screening laboratory tests. During this period, participants will also have a posteroranterior (PA) and Lateral chest X-ray (CXR), and a baseline 12-lead ECG.

After screening, eligible participants will be admitted to an inpatient challenge unit (Day -2). Up to twelve participants will be enrolled of which up to 6 participants will have H3N2 challenge titers <40 and up to 6 participants will have H3N2 challenge titers >40. The plan is to enroll participants with the broadest range of MN titers. Based on the results of the MN titers, participants may be healthy but may not be enrolled. Backup participants may be admitted into the inpatient unit to ensure sufficient number of volunteers undergo CHI, given the potential for drop-outs, presence of new exclusionary criteria, and/or pre-challenge evidence of viral respiratory infection among participants. A review of eligibility criteria, and baseline clinical assessments, safety blood tests, influenza virology, and immunology tests will be performed and the participants will have approximately a 48-hour window to decide if they would like to drop out of the study and leave the inpatient unit before CHI. Participants must have no evidence of a respiratory viral infection as determined by multiplex respiratory virus RT-PCR assay testing prior to CHI (positive results prior to CHI will exclude the subject from the challenge, and additional participants may serve as replacements). On Day -1, participants will be trained on the influenza patient related outcomes Flu-PRO Survey Instrument and Validation Diary.

On Day 1, eligibility and clinical status will be reviewed. If criteria for proceeding with challenge are met, participants will receive A/Texas/71/2017 (H3N2), clade 3C3a CHI. 0.5 mL of RG-A/Texas/71/2017 (H3N2) influenza, clade 3C3a will be delivered in each nostril of a recumbent participants per study SOP. Backups will be discharged from the inpatient unit prior to challenging other participants if not needed to replace ineligible participants or participants declining to proceed with CHI.

After CHI, participants will complete daily self-assessments using the Flu-PRO Survey Instrument and Validation Diary through 14 days post-challenge to generate a symptom severity score. Participant clinical status will be monitored closely. Safety labs will be performed at scheduled times. Participants will undergo scheduled blood draws, and nasal swab collections for immunology and virologic laboratory testing. Quantitative and qualitative evaluation of influenza will be done after CHI on Day 7. Participants will also undergo qualitative evaluations for evidence of influenza by multiplex respiratory virus RT-PCR assay. Participants will speak/breathe into the PathoSift Pro which is a Bioaerosol Sampler device for 15-30 minutes every other day while in the confinement unit to collect airborne viruses. Participants will remain blinded to the results of their respiratory virus testing until they meet discharge criteria. An ECG will be performed at Day 6 on all participants, and as clinically indicated at any other time.

Following CHI, participants will remain in the inpatient unit for a minimum of seven additional days and will be discharged only if 1) they have two consecutive negative influenza tests (that are performed on days 7 and 8) for influenza A using a multiplex respiratory virus assay (BIOFIRE® FILMARRAY® or Luminex xTAG®), AND 2) have been afebrile (<38.0°C), have a room air Saturation of Peripheral Oxygen (SpO2) ≥95 and have been clinically and hemodynamically stable for at least 48 hours. In addition, participants may have residual and/or resolving symptoms of influenza illness. It is expected that most participants will shed the challenge virus for three to five days post exposure.

If participants are still shedding virus on Day 8, they will remain in the challenge unit, be offered one dose of baloxavir marboxil (a full treatment course), and they will continue to have NP swabs tested daily until there are two negative influenza tests performed on consecutive days and meet clinical discharge criteria described above.

Any participant who develops serious related or unrelated signs or symptoms during inpatient stay will receive appropriate and as clinically necessary escalation of care (e.g., cardiologist consultation for cardiac symptoms or transfer for evaluation at the Emergency Department). Any participant who experiences complications or sequelae due to CHI will be followed until resolution and/or stable, and will be referred for appropriate specialized care as clinically necessary. All participants will be followed for approximately 90 days post-challenge. Additional follow-up will be performed at in-person Visits 9 (Day 15), 10 (Day 29) and 11 (Day 61). Participants will also undergo scheduled blood draws and nasopharyngeal (NP) swabs for immunology and virologic laboratory testing during this follow up period. A final follow-up by telephone will occur on Visit 12 (Day 91).

Conditions

Influenza

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Single Arm

One dose of RG-A/Texas/71/2017 Influenza Virus

Group Type: EXPERIMENTAL

A/Texas

Intervention Type: BIOLOGICAL

Live Influenza Virus RG-A/Texas/71/2017 H3N2 Dose: 1.0 mL (0.5mL per nostril) of approximately 1x10\^6 TCID50 Administered intranasally by atomizer device Challenge virus will be administered once on Day 1

Interventions

A/Texas

Live Influenza Virus RG-A/Texas/71/2017 H3N2 Dose: 1.0 mL (0.5mL per nostril) of approximately 1x10\^6 TCID50 Administered intranasally by atomizer device Challenge virus will be administered once on Day 1

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Provide written informed consent prior to initiation of any study procedure.

2. Are able to understand and comply with planned study procedures and be available for all study visits.

3. Agree to remain an inpatient for at least seven days after challenge, AND until they have no virus shedding,1 determined by qualitative RT-PCR for a minimum of two consecutive days post-challenge 1For a minimum of seven days post-challenge (Study Day 8).

4. Healthy2 males and non-pregnant, non-breastfeeding females3 aged ≥18 and ≤45 years of age, inclusive, at enrollment.

5. Women of childbearing potential4 must agree to use or have practiced true abstinence5 or use at least 1 acceptable primary form of contraception6,7 These criteria are applicable to females in a heterosexual relationship and child-bearing potential (i.e., the criteria do not apply to participants in a same sex relationship).

4Not of child- bearing potential - post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or Essure® placement with history of documented radiological confirmation test at least 90 days after the procedure).

5True abstinence is 100% of time no sexual intercourse (male's penis enters the female's vagina). (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).

6Acceptable forms of primary contraception include intrauterine devices, birth control pills, and injectable/implantable/insertable hormonal birth control products monogamous relationship with a vasectomized partner who has been vasectomized for180 days or more prior to the subject receiving the influenza challenge virus.

7Must use at least one acceptable primary form of contraception for at least 30 days prior to admission and at least one acceptable primary form of contraception during the remainder of the study.

6. Non-habitual smoker8 of tobacco, or marijuana. 8Non-habitual smokers are those who smoke no more than four cigarettes, other tobacco products, vaping (e-cigarettes) or marijuana in a week for more than three months and agree not to smoke cigarettes, other tobacco products, e-cigarettes and/or marijuana products during participation in the study.

7. No self-reported or known history of alcoholism or drug use within the last 30 days and agrees to abstain from alcohol and drugs9 for at least one week before admission and throughout the inpatient period.

9 including forms of marijuana not included in criterion 6 8. Negative drug urine toxicology result on screening (i.e., amphetamines, cocaine, and opiates). and on admission to the challenge unit (i.e., amphetamines, cocaine, and opiates).

9. Agree not to use the listed10 prescription or over-the-counter medications within 7 days prior to inpatient stay and through inpatient stay, unless approved by the investigator.

10Oseltamivir, zanamivir, peramivir, baloxavir marboxil, amantadine (generic) and rimantadine (Flumadine and generic), aspirin, intranasal steroids, decongestants, antihistamines, and other non-steroidal anti-inflammatory drugs (NSAIDs).

Exclusion Criteria

11. Does not have an ongoing symptomatic condition12 for which subject has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.

12e.g., ongoing fatigue without a diagnosis for symptom. 12. Vital signs as follows13: 13pulse is 47 to 99 beats per minute, inclusive; systolic blood pressure is 85 to 139 mmHg, inclusive; diastolic blood pressure is 55 to 89 mmHg, inclusive; SpO2 >95%; RR<18; oral temperature is less than 100.0°F.

13. Eligibility laboratory values (WBC, Absolute Lymphocyte Count, Hgb, PLTs, ALT and Cr) are within acceptable parameters.

14. Body mass index (BMI) >18.5 and <35 kg/m2 at screening. 15. Other screening tests (ECG and CXR) are within normal reference range or not deemed clinically significant by the PI or appropriate sub-investigator14 14Designated clinician licensed to make medical diagnoses and listed on the Form FDA 1572 16. H3N2 Challenge virus MN titer done in SLU VTEU research lab during screening to allow selection for enrollment of subjects with the broadest range of pre-existing H3N2 immunity.

17. Negative test for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) at screening blood draw.

18. Negative respiratory virus panel by BIOFIRE® FILMARRAY® respiratory panel by bioMérieux or by Luminex xTAG® on Day -2, and Day -1.

1. Female subject who has a positive pregnancy test on screening or admission, is breastfeeding or planning to become pregnant from 30 days prior to challenge through the end of the study.

2. Presence of self-reported or medically documented significant medical or psychiatric condition(s)15 15Significant medical or psychiatric conditions include but are not limited to:

1. Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma) requiring daily medications15 currently or any treatment of respiratory disease exacerbations (e.g., asthma exacerbation) in the last 5 years 16Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.

2. Presence of any febrile illness or symptoms suggestive of a respiratory infection within two weeks prior to CHI.

3. Cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.

4. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barre syndrome, encephalomyelitis or transverse myelitis).

5. Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding basal cell carcinoma of the skin, which is allowed.

6. An autoimmune disease.

7. An immunodeficiency of any cause.

8. A history of diabetes.

3. Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness17- 17Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 12-month period prior to screening. Low dose topical and intranasal steroid preparations used for a discrete period of time are permitted (Section 7.1).

4. Known allergy or intolerance to treatments for influenza (including but not limited to oseltamivir, baloxavir marboxil, acetaminophen).

5. Known allergy to two or more classes of antibiotics (e.g., penicillins, cephalosporins, fluoroquinolones, or glycopeptides).

6. Known allergy to excipients in the challenge virus inoculum.

7. Receipt or planned receipt of any investigational drug/investigational vaccine/licensed vaccine within 30 days prior to the date of CHI.

8. Prior enrollment in any influenza virus challenge study.

9. Currently enrolled in any investigational study or intends to enroll in such a study within the ensuing study period.

10. Receipt of any influenza vaccine six months prior to challenge or plans to receive influenza vaccine within 60 days post-challenge.

11. History of a previous severe allergic reaction of any kind with generalized urticaria, angioedema, or anaphylaxis.

12. Receipt of blood or blood products during the six months prior to the planned date of challenge.

13. History of blood donation during the two months prior to the planned date of challenge and or plans to donate blood for the duration of the study.

14. Any condition, to include medical and psychiatric conditions, that in the opinion of the Investigator, might interfere with the safety of the subject and/or study objectives.

15. Known close contact with anyone known to have influenza 7 days prior to challenge.

16. Acute medical condition with new prescription medication use in the last 30 days.

17. Significant abnormality altering the anatomy of the nose/nasopharynx18 clinically significant nasal deviation, or nasal/sinus surgery within 180 days prior to challenge.

18including significant nasal polyps. 18. History in the last five years of chronic or frequent intermittent sinusitis.

19. Recent history (180 days) of epistaxis or anatomic or neurologic abnormality impairing the gag reflex or contributing to aspiration.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Daniel Hoft, MD, PhD

OTHER

Sponsor Role: lead

Responsible Party

Daniel Hoft, MD, PhD

Professor of Internal Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Daniel F. Hoft, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Saint Louis University Center for Vaccine Development

Locations

Saint Louis University Center for Vaccine Development

St Louis, Missouri, United States

Countries

United States

References

22. Centers for Disease Control and Prevention. People at High Risk For Flu Complications. Available at: https://www.cdc.gov/flu/highrisk/index.htm. Accessed 14 February 2025.

Reference Type: BACKGROUND

Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33(1):1-22.

Reference Type: BACKGROUND

PMID: 20808728 (View on PubMed)

Hasing ME, Hazes B, Lee BE, Preiksaitis JK, Pang XL. A next generation sequencing-based method to study the intra-host genetic diversity of norovirus in patients with acute and chronic infection. BMC Genomics. 2016 Jul 1;17:480. doi: 10.1186/s12864-016-2831-y.

Reference Type: BACKGROUND

PMID: 27363999 (View on PubMed)

Powers JH, Guerrero ML, Leidy NK, Fairchok MP, Rosenberg A, Hernandez A, Stringer S, Schofield C, Rodriguez-Zulueta P, Kim K, Danaher PJ, Ortega-Gallegos H, Bacci ED, Stepp N, Galindo-Fraga A, St Clair K, Rajnik M, McDonough EA, Ridore M, Arnold JC, Millar EV, Ruiz-Palacios GM. Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis. 2016 Jan 5;16:1. doi: 10.1186/s12879-015-1330-0.

Reference Type: BACKGROUND

PMID: 26729246 (View on PubMed)

18. Food and Drug Administration. Highlights of Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf. Accessed 14 February 2025.

Reference Type: BACKGROUND

Kaji M, Watanabe A, Aizawa H. Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients. Respirology. 2003 Jun;8(2):231-3. doi: 10.1046/j.1440-1843.2003.00457.x.

Reference Type: BACKGROUND

PMID: 12753540 (View on PubMed)

Shetty N, Shephard MJ, Rockey NC, Macenczak H, Traenkner J, Danzy S, Vargas-Maldonado N, Arts PJ, Le Sage V, Anderson EJ, Lyon GM, Fitts EC, Gulick DA, Mehta AK, El-Chami MF, Kraft CS, Wigginton KR, Lowen AC, Marr LC, Rouphael NG, Lakdawala SS. Influenza virus infection and aerosol shedding kinetics in a controlled human infection model. J Virol. 2024 Dec 17;98(12):e0161224. doi: 10.1128/jvi.01612-24. Epub 2024 Nov 26.

Reference Type: BACKGROUND

PMID: 39589151 (View on PubMed)

Ortiz JR, Bernstein DI, Hoft DF, Woods CW, McClain MT, Frey SE, Brady RC, Bryant C, Wegel A, Frenck RW, Walter EB, Abate G, Williams SR, Atmar RL, Keitel WA, Rouphael N, Memoli MJ, Makhene MK, Roberts PC, Neuzil KM. A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 Aug 11;228(3):287-298. doi: 10.1093/infdis/jiad021.

Reference Type: BACKGROUND

PMID: 36702771 (View on PubMed)

Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT Jr, Taubenberger JK. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. mBio. 2016 Apr 19;7(2):e00417-16. doi: 10.1128/mBio.00417-16.

Reference Type: BACKGROUND

PMID: 27094330 (View on PubMed)

Memoli MJ, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K, Fargis S, Stein M, Dunfee RL, Shaw PA, Davey RT, Taubenberger JK. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis. 2015 Mar 1;60(5):693-702. doi: 10.1093/cid/ciu924. Epub 2014 Nov 20.

Reference Type: BACKGROUND

PMID: 25416753 (View on PubMed)

Ison MG, Campbell V, Rembold C, Dent J, Hayden FG. Cardiac findings during uncomplicated acute influenza in ambulatory adults. Clin Infect Dis. 2005 Feb 1;40(3):415-22. doi: 10.1086/427282. Epub 2005 Jan 10.

Reference Type: BACKGROUND

PMID: 15668866 (View on PubMed)

Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther. 2005;10(8):901-10.

Reference Type: BACKGROUND

PMID: 16430195 (View on PubMed)

Waldock J, Cox RJ, Chiu C, Subbarao K, Wildfire A, Barclay W, van Kasteren PB, McCauley J, Russell CA, Smith D, Thwaites RS, Tregoning JS, Engelhardt OG. Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK. Influenza Other Respir Viruses. 2024 Nov;18(11):e70014. doi: 10.1111/irv.70014.

Reference Type: BACKGROUND

PMID: 39496425 (View on PubMed)

Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008 Apr 1;167(7):775-85. doi: 10.1093/aje/kwm375. Epub 2008 Jan 29.

Reference Type: BACKGROUND

PMID: 18230677 (View on PubMed)

Taaffe J, Ostrowsky JT, Mott J, Goldin S, Friede M, Gsell P, Chadwick C. Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact. Vaccine. 2024 Dec 2;42(26):126408. doi: 10.1016/j.vaccine.2024.126408. Epub 2024 Oct 5.

Reference Type: BACKGROUND

PMID: 39369576 (View on PubMed)

7. Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. U.S. DHHS, FDA, CBER, May 2007.

Reference Type: BACKGROUND

Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 2018 Jul 2;218(3):347-354. doi: 10.1093/infdis/jiy103.

Reference Type: BACKGROUND

PMID: 29506129 (View on PubMed)

5. COVID-19. Available at https://cepi.net/COVID-19. Accessed 13 February 2025.

Reference Type: BACKGROUND

2. CDC Seasonal Flu Vaccine Effectiveness Studies. Available at https://www.cdc/gpv/flu-vaccines-work/php/effectiveness-studies/index,html. Accessed 13 February 2025.

Reference Type: BACKGROUND

Mao T, Israelow B, Pena-Hernandez MA, Suberi A, Zhou L, Luyten S, Reschke M, Dong H, Homer RJ, Saltzman WM, Iwasaki A. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science. 2022 Nov 25;378(6622):eabo2523. doi: 10.1126/science.abo2523. Epub 2022 Nov 25.

Reference Type: BACKGROUND

PMID: 36302057 (View on PubMed)

Gagne M, Flynn BJ, Andrew SF, Marquez J, Flebbe DR, Mychalowych A, Lamb E, Davis-Gardner ME, Burnett MR, Serebryannyy LA, Lin BC, Ziff ZE, Maule E, Carroll R, Naisan M, Jethmalani Y, Pessaint L, Todd JM, Doria-Rose NA, Case JB, Dmitriev IP, Kashentseva EA, Ying B, Dodson A, Kouneski K, O'Dell S, Wali B, Ellis M, Godbole S, Laboune F, Henry AR, Teng IT, Wang D, Wang L, Zhou Q, Zouantchangadou S, Van Ry A, Lewis MG, Andersen H, Kwong PD, Curiel DT, Roederer M, Nason MC, Foulds KE, Suthar MS, Diamond MS, Douek DC, Seder RA. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nat Immunol. 2024 Oct;25(10):1913-1927. doi: 10.1038/s41590-024-01951-5. Epub 2024 Sep 3.

Reference Type: BACKGROUND

PMID: 39227514 (View on PubMed)

Taubenberger JK, Morens DM. The 1918 Influenza Pandemic and Its Legacy. Cold Spring Harb Perspect Med. 2020 Oct 1;10(10):a038695. doi: 10.1101/cshperspect.a038695.

Reference Type: BACKGROUND

PMID: 31871232 (View on PubMed)

Other Identifiers

SLU-25-001

Identifier Type: -

Identifier Source: org_study_id